---
title: Pediatric relapsed/refractory ALK+ anaplastic large cell lymphoma treatment
  and outcomes in the targeted drug era
date: '2025-01-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39841960/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250123170651&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Treatment options for patients with relapsed or refractory (R/R) anaplastic
  large cell lymphoma (ALCL) have increased in the era of targeted therapies such
  as brentuximab vedotin (BV) and Anaplastic Lymphoma Kinase (ALK) inhibitors. However,
  there is no standard treatment and limited published data evaluating their use.
  The goal of this retrospective study is to describe current real-world treatment
  and outcomes of pediatric, adolescent, and young adult patients with R/R ALK-positive
  ALCL. ...
disable_comments: true
---
Treatment options for patients with relapsed or refractory (R/R) anaplastic large cell lymphoma (ALCL) have increased in the era of targeted therapies such as brentuximab vedotin (BV) and Anaplastic Lymphoma Kinase (ALK) inhibitors. However, there is no standard treatment and limited published data evaluating their use. The goal of this retrospective study is to describe current real-world treatment and outcomes of pediatric, adolescent, and young adult patients with R/R ALK-positive ALCL. ...